SCHEMBL7128742

SCHEMBL7128742

COc1cccc(CNC(=O)c2cccc3c2C(S(=O)(=O)c2ccccc2)CS3(=O)=O)c1OC

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.45
HPGD P15428 5/20 0.44
ROCK2 O75116 1/20 0.43
ROCK1 Q13464 1/20 0.43
NAMPT P43490 1/20 0.43
ALDH1A1 P00352 5/20 0.43
KDM4E B2RXH2 2/20 0.43
GAA P10253 2/20 0.42
KMT2A Q03164 2/20 0.42
RCE1 Q9Y256 1/20 0.41
LMNA P02545 2/20 0.41
S1PR1 P21453 1/20 0.41
PKM P14618 1/20 0.40
HTT P42858 1/20 0.40
MAPT P10636 1/20 0.40
MAOB P27338 1/20 0.40
MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7128598 0.94 HPGD (0.52) RAB9AHPGDALDH1A1KDM4EGAA
SCHEMBL7128736 0.91 RAB9A (0.45) RAB9AHPGDROCK2ROCK1NAMPT
SCHEMBL7132804 0.88 APEX1 (0.45) RAB9AHPGDNAMPTALDH1A1GAA
SCHEMBL7131434 0.87 TAS1R3 (0.54) RAB9AHPGDNAMPTALDH1A1KDM4E
SCHEMBL7132354 0.85 KMT2A (0.46) ALDH1A1KDM4EKMT2ALMNAMEN1
SCHEMBL7128593 0.85 HPGD (0.52) RAB9AHPGDALDH1A1KDM4EGAA
SCHEMBL7129946 0.84 PTPN1 (0.44) RAB9AHPGDALDH1A1KDM4EGAA
SCHEMBL7126241 0.84 APEX1 (0.52) RAB9AHPGDALDH1A1LMNAMAPT
SCHEMBL7128745 0.83 POLB (0.48) HPGDALDH1A1KMT2ALMNAPKM
SCHEMBL7128198 0.82 POLB (0.41) RAB9AROCK2ROCK1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030073706-A1 Fused thiophone derivatives and drugs containing the same as the active ingredient KONISHI MIKIO (JP) 2003-04-17 US claimed
US-6420391-B1 PREVENTION AND/OR TREATMENT OF VARIOUS INFLAMMATORY DISEASES, SEPSIS, MULTIPLE MYELOMA, PLASMA CELL LEUKEMIA, OSTEOPOROSIS, CACHEXIA, PSORIASIS, NEPHRITIS, RENAL CELL CARCINOMA, KAPOSI'S SARCOMA, RHEUMATOID ARTHRITIS, GAMMOPATHY, CASTLEMAN'S ONO PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 US claimed
EP-1067128-A1 FUSED THIOPHENE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2001-01-10 EP claimed
US-6555555-B1 Inhibitors of interleukin-6 and/or interleukin-12; for example 4,5-dimethyl-1,1-dioxidebenzo(b)thiophene; treating various inflammatory diseases, autoimmune diseases, cancer, osteoporosis ONO PHARMACEUTICAL CO., LTD. (JP) 2003-04-29 US disclosed
US-20030073706-A1 Fused thiophone derivatives and drugs containing the same as the active ingredient KONISHI MIKIO (JP) 2003-04-17 US disclosed
US-6420391-B1 PREVENTION AND/OR TREATMENT OF VARIOUS INFLAMMATORY DISEASES, SEPSIS, MULTIPLE MYELOMA, PLASMA CELL LEUKEMIA, OSTEOPOROSIS, CACHEXIA, PSORIASIS, NEPHRITIS, RENAL CELL CARCINOMA, KAPOSI'S SARCOMA, RHEUMATOID ARTHRITIS, GAMMOPATHY, CASTLEMAN'S ONO PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 US disclosed
EP-1067128-A1 FUSED THIOPHENE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2001-01-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073706-A1 Fused thiophone derivatives and drugs containing the same as the active ingredient TPMT, CD47, THPO RAB9A 4644/4885HPGD 2671/4885ROCK2 4253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.